Skip to content
The Kids Research Institute Australia logo
Donate

Search

Funding boost for groundbreaking child health research

Researchers from The Kids Research Institute Australia will share in almost $4 million in grants to continue groundbreaking research to tackle childhood cancer, asthma, respiratory viral infections and more.

Giving kids with CF a chance at a longer, healthier life

COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.

Funding boost for cancer, antimicrobial resistance, and pain management treatments

The Kids Research Institute Australia researchers will share in $2.3 million awarded by the Western Australian Department of Health Innovation Seed Fund.

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases

Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient's genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design.

The Kids researchers named as finalists in 2023 Premier’s Science Awards

Five The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.

The Kids Research Institute Australia researchers awarded $11 million to support vital child health research

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.

An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapies

Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.

Biodiesels not as clean and green as they seem

In a world being urged to embrace renewable options, biodiesel fuels are increasingly being touted as a greener, cleaner choice than traditional diesel.

How summer bushfires can impact your family’s health

Bushfires can have a considerable impact on our health, with some symptoms lasting long after the flames are extinguished. And our children are amongst the most vulnerable.

Wearable devices could change clinical care for kids with cystic fibrosis

A bold respiratory research project will investigate whether wearable devices could drastically change clinical care for children living with chronic diseases such as cystic fibrosis.